Definitions of variables and measurements. by Getachew Magnar Kitila (19935139)

Regression estimates: Double threshold model. by Getachew Magnar Kitila (19935139)

Results from cross sectional dependence test. by Getachew Magnar Kitila (19935139)

Panel quantile regression results. by Getachew Magnar Kitila (19935139)

The raw data for Fig 8A. by Hongjoo An (21703199)

Demographic information. by Silas Manning (22693338)

“…These results highlight decreased sound tolerance as a significant issue at Canadian post-secondary institutions, calling for steps to be taken to mitigate its effects.…”

Age-Period-Cohort Model Analysis of Gastric Cancer Incidence and Mortality in Taiwan. by Xiaohuang Yang (10182727)

Trends of age-specific burden of gastric cancer in Taiwan by gender from 1990 to 2021. by Xiaohuang Yang (10182727)

Projections of Gastric Cancer Incidence and Mortality Burden in Taiwan Through 2036. by Xiaohuang Yang (10182727)

Comparison of the burden of gastric cancer by age in Taiwan between 1990 and 2021. by Xiaohuang Yang (10182727)

Age-specific numbers and rates of incidence, prevalence, deaths and DALYs for gastric cancer in Taiwan, 2021. by Xiaohuang Yang (10182727)

Joinpoint Analysis of ASIR, ASPR, ASMR, and ASDR of gastric cancer in Taiwan, 1990–2021. by Xiaohuang Yang (10182727)

Microscopic examination of fetal placenta exposed to <i>U.simensis</i> essential oil: D-decidua, DA-decidual artery, DV-decidual vein, blue arrow head-maternal blood space, CBV-cho... by Bickes Wube (21678222)

AUC of various models to predict imeglimin efficacy for liver function evaluated by ROC curves. by Naruyoshi Gyoutoku (22537831)

Logistic regression analysis to predict the efficacy for liver function. by Naruyoshi Gyoutoku (22537831)

Clinical characteristics at baseline and at the end of the study. by Naruyoshi Gyoutoku (22537831)

Comparison in baseline variables between efficacy group and non-efficacy group. by Naruyoshi Gyoutoku (22537831)

Comparison of ALT (A), AST (B), and Fib-4 index (C) before and after imeglimin treatment in ALT ≥ 25 IU/L and ALT < 25IU/L groups. by Naruyoshi Gyoutoku (22537831)

HEK.219 cells were treated with the indicated siRNAs for 24h. by Lorenza Cutrone (21144285)

HSF2 expression sustains KSHV infection in KLEC. by Lorenza Cutrone (21144285)